Status:
UNKNOWN
Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Urolithiasis
Nephrolithiasis
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
The minimally-invasive extracorporeal shockwave lithotripsy (ESWL) procedure is generally considered the best first-line treatment option for most adults and children with nephrolithiasis, especially ...
Detailed Description
The present study takes the form of a double-blind, randomized clinical trial. The study conforms to the principles stated in the Declaration of Helsinki. Written informed consent is obtained from all...
Eligibility Criteria
Inclusion
- Age 18 to 60 years
- Patients with renal or ureteral calculi referred by attending urologists to the ESWL Clinic of Shahid Faghihi Hospital, affiliated to Shiraz University of Medical Sciences (Shiraz, Iran)
Exclusion
- An anatomic anomaly in urinary system
- Coagulopathy
- Untreated urinary tract infection
- Prior urologic surgery
- Simultaneous unilateral renal and ureteral stones
- Kidney failure (serum creatinine \> 1.8 mg/dl)
- Cardiovascular disease
- Hypertension
- Morbid obesity (BMI \> 40 kg/m2)
- History of allergy to furosemide, glibenclamide, hydrochlorothiazide, or acetazolamide.
- Pregnancy
- Single kidney
Key Trial Info
Start Date :
July 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05270421
Start Date
July 1 2020
End Date
July 30 2022
Last Update
March 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shahid Faghihi Hospital
Shiraz, Fars, Iran, 71348-14336